Loading clinical trials...

Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab | Clinical Trials | Clareo Health

COMPLETED

Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab

Real-World Outcome of Psoriasis Patients in Korea on Adalimumab

NCT03099083•AbbVie

Summary

The objective of this non-interventional, observational study is to assess the effect of adalimumab on health-related quality of life in participants with Psoriasis in Korea.

Eligibility

Age

19 - 99 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participant has a diagnosis of Psoriasis by investigator.
•Participant (local definition according to adalimumab label) who is in compliance with eligibility for adalimumab based on the local label.
•Participant must be able and willing to provide written informed consent and comply with the requirements of this study protocol.

Exclusion Criteria

•Participants who are pregnant or breast feeding at enrolment or wish to become pregnant in the next 24 weeks.
•Participation in any Psoriasis-related clinical trial at the time of enrolment, at baseline or at any point during the study period.
•Participants, who in the investigator's view, may not be able to accurately report their questionnaires

Locations (12)

Hallym University Sacred Heart Hospital /ID# 161697

Anyang-si, Gyeonggi-do, Gyeonggido, South Korea

CHA Bundang Medical center, CHA University /ID# 161696

Seongnam-si, Gyeonggido, South Korea

Ajou University Hospital /ID# 161698

Suwon, Gyeonggido, South Korea

Yonsei University Health System, Severance Hospital /ID# 166300

Seodaemun-gu, Seoul Teugbyeolsi, South Korea

Hanyang University Seoul Hospi /ID# 169553

Seongdong-gu, Seoul Teugbyeolsi, South Korea

Busan National University Hosp /ID# 166299

Busan, South Korea

Inje University Ilsan Paik Hos /ID# 166302

Goyang, South Korea

Korea University Ansan Hosp /ID# 161695

Gyeonggi-do, South Korea

Korea University Ansan Hosp /ID# 161699

Gyeonggi-do, South Korea

Kyunghee University Hospital /ID# 161694

Seoul, South Korea

Key Dates

Start Date

March 31, 2017

Primary Completion Date

April 5, 2019

Completion Date

April 5, 2019

Last Updated

March 30, 2020

Enrollment

ACTUAL participants

Conditions

Psoriasis

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

NCT07449234

Psoriasis

View study

RECRUITINGPHASE3

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967

Plaque Psoriasis

View study

RECRUITINGPHASE3

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 30, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab

Inclusion Criteria

Exclusion Criteria

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Real-Life Evaluation of Guselkumab Dosing Interval Adjustments